RESUMO
Introduction Research integrity is an active adherence to the ethical principles and professional standards essential for the responsible practice of research. Research or scientific misconduct stands like child abuse today. The survey of National Institutes of Health (NIH)-funded scientists calculated an absolute minimum of 2325 incidents of scientific misconduct per year. A report has also shown that Iran (6.60), India (5.68), Turkey (5.38), South Korea (3.59), and China (2.00) had higher ratios of publication misconduct to distrust data or interpretations than other countries. Hence, to determine the knowledge, attitude, and practices (KAPs) of the research integrity/scientific misconduct among the faculty and postgraduates working in the medical colleges in North Karnataka (NK) and Central India (CI), this study has been carried out. Methods It is a web-based, cross-sectional study carried out with the use of Google Forms (Google, Mountain View, California). A pretested, unstructured questionnaire consisting of 25 questions was posted in the way of a link to the faculty and postgraduates working in various disciplines within the colleges of NK and CI either by using an e-mail or other social platforms like WhatsApp. Institutional Ethics Committee approval was obtained in both regions before conducting the survey. Results A total of 146 participants responded to the e-questionnaire posted to them. Participants from CI displayed better awareness in several areas compared to NK. Citing articles and/ or materials that have not been read is the common questionable research practice (QRP) they have come across, as mentioned by participants in both groups. Discussion The study reveals a moderate level of knowledge and variable attitudes toward research integrity. The "publish or perish" culture is a major contributor to misconduct. Training and awareness programs are needed to enhance ethical research practices. Conclusion This study highlights the need for improved education and policy implementation to uphold research integrity in medical colleges, emphasizing the role of academic culture in shaping ethical research practices.
RESUMO
Background Cutaneous adverse drug reactions (ADRs) are among the most frequent ADRs. Knowledge of the pattern of cutaneous ADRs (CADRs) and causal drugs helps prevent and reduce the incidence of CADR, which in turn reduces the incidence of hospitalization and expenses for the patient. Objectives To analyze CADR according to demographic profile, morphological pattern, causative drugs, severity, and outcome in patients suffering from CADRs. Materials and methods Retrospective data analysis was conducted in the Adverse Drug Reaction Monitoring Centre (AMC) of the tertiary care teaching institute between February 2020 and September 2023 under the Pharmacovigilance Program of India (PvPI). All ADRs reported were analyzed based on the following parameters: total number of ADRs reported, number of CADRs, information related to demographic parameters, the clinical presentation of CADRs, and suspected medication. Causality assessment was done using the World Health Organisation-Uppsala Monitoring Centre (WHO-UMC) scale. Severity was assessed using a modified Hartwig and Seigel scale. Results A total of 125 CADRs were analyzed. Considering the gender-wise distribution, 65 females and 60 males suffered from CADR. The most common drug category responsible for CADRs was antimicrobials (63.2%), followed by topical agents (12.8%). Maculopapular rash (33.6%) was the most common presenting symptom, followed by itching (27.2%). Few patients suffered from serious CADRs such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Conclusion A wide clinical spectrum of CADRs ranging from maculopapular rash to fixed-drug eruption to serious SJS was observed in our study. The most common causative agents for CADRs were antimicrobials, followed by topical agents and NSAIDs. For early diagnosis and management of CADRs, it is critical to have data on the potential cutaneous adverse effects of commonly used drugs, to educate the patients regarding common early symptoms of drug reactions (e.g., erythematous rash, edema, urticaria, mucosal erosions, itching, burning of skin, etc.), and to monitor the patient, especially during the start of therapy. To ease the burden of CADRs, a therapeutic plan of anticipating, avoiding, recognizing, and responding to ADRs should be implemented.
RESUMO
Background Cardiovascular autonomic neuropathy (CAN), an important form of DAN is caused by the impairment of the autonomic nerve fibers that innervate the heart and blood vessels and leads to abnormalities in cardiovascular dynamics. The earliest finding of CAN, even at the subclinical stage, is a decrease in heart rate variability (HRV). Objective The objective is to assess the effect of ramipril 2.5mg once daily on cardiac autonomic neuropathy in type II DM patients as an add-on to a standard antidiabetic regimen for a duration of 12 months. Materials and methods A prospective, open-label, randomized, parallel-group study was conducted on type II DM with autonomic dysfunction. Patients in Group A received tablet ramipril 2.5mg daily along with the standard antidiabetic regimen which consist of Tab Metformin 500mg twice a day and Tab Vildagliptin 50mg twice a day and group B received only the standard antidiabetic regimen for 12 months. Results Among 26 patients with CAN, 18 patients completed the study. After one year in group A, Delta HR value increases from 9.77±1.71 to 21.44±8.44 and the E:I ratio (ratio of the longest R-R interval during expiration and shortest R-R interval during inspiration) improved from 1.23±0.35 to 1.29±0.23 signifying significant improvement in parasympathetic tone. Results of the postural test showed significant improvement in SBP. Analysis of HRV by time domain method showed that the standard deviation of RR (SDRR) interval and Standard deviation of differences between adjacent RR interval (SDSD) value increased significantly in group A. Analysis of HRV frequency domain indices showed that LFP:HFP ratio improved after treatment in ramipril group indicating improvement in sympatho-vagal balance. Conclusion Ramipril improves parasympathetic component more as compared to sympathetic component of DCAN in type II DM. Ramipril could be a promising option having favorable long-term outcomes in diabetic patients especially when treatment begins at subclinical stage.
